This editorial refers to ‘High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial’, by M. Pareek et al., and ‘Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial’, by M. Pareek et al.

Read the full editorial (European Heart Journal (2025) 46, 4299–4301) here!